"bcCategories","studyEstimands","id","studyInvestigationalInterventions","documentVersion","uuid:ID","label","studyDesignRationale","name","description"
"[]","[]","StudyDesign_1","[]","","1222923d-9086-4946-ab75-86e98d9c75ed","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study"
